Subtopic Deep Dive
Glycosylation Engineering in Transgenic Plants
Research Guide
What is Glycosylation Engineering in Transgenic Plants?
Glycosylation engineering in transgenic plants modifies plant N-glycosylation pathways to produce human-like glycoproteins for mammalian therapeutics by targeting glycosyltransferases and eliminating plant-specific glycans.
Plants naturally add β1,2-xylose and α1,3-fucose to N-glycans, causing immunogenicity in humans (Strasser et al., 2008; Strasser, 2016). Researchers use RNA interference and glycosyltransferase overexpression in Nicotiana benthamiana and Lemna minor to generate homogeneous human-like N-glycans on monoclonal antibodies and enzymes (Strasser et al., 2008; Cox et al., 2006). Over 10 key papers since 1999 document these advances, with Strasser et al. (2008) cited 516 times.
Why It Matters
Human-like glycosylation ensures protein stability, efficacy, and low immunogenicity for biotherapeutics produced in plants, reducing costs compared to mammalian cell systems (Strasser et al., 2008; Cox et al., 2006). Strasser et al. (2008) demonstrated glyco-engineered Nicotiana benthamiana producing monoclonal antibodies with homogeneous GnGn structures compatible with human therapy. Cox et al. (2006) optimized glycan structures in Lemna minor for a human monoclonal antibody, enabling scalable plant-based manufacturing. Strasser (2016) reviews plant glycosylation differences, highlighting engineering needs for therapeutic proteins like glucocerebrosidase (Shaaltiel et al., 2007).
Key Research Challenges
Eliminating Plant-Specific Glycans
Plants add β1,2-xylosyl and α1,3-fucosyl residues absent in humans, triggering immune responses (Strasser et al., 2008). RNA interference knocks out XylT and FucT genes in Nicotiana benthamiana to produce human-like GnGn structures (Strasser et al., 2008). Balancing glycan homogeneity with plant growth remains difficult (Strasser, 2016).
Achieving Complex Human Glycans
Plants lack mammalian glycosyltransferases for sialylated and branched N-glycans essential for protein half-life (Cox et al., 2006). Overexpression of human β1,4-GalT and α2,6-sialyltransferase in Lemna minor enables partial humanization (Cox et al., 2006). Full pathway reconstruction faces metabolic competition issues (Strasser, 2016).
Scaling Therapeutic Production
Engineered plants must yield high glycoprotein quantities without immunogenicity for clinical use (Shaaltiel et al., 2007). Shaaltiel et al. (2007) produced mannose-terminated glucocerebrosidase in plant cells for Gaucher's disease therapy. Productivity and purification challenges persist in large-scale hydroponic systems (Strasser et al., 2008).
Essential Papers
Essentials of Glycobiology
Ajit Varki, Richard D. Cummings, Jeffrey D. Esko et al. · 1999 · 2.5K citations
General principles - historical background and overview saccharide structure and nomenclature evolution of glycan diversity protein-glycan Interactions exploring the biological roles of glycans bio...
<i>Pichia pastoris</i>: A highly successful expression system for optimal synthesis of heterologous proteins
Mohsen Karbalaei, Seyed Abdolrahim Rezaee, Hadi Farsiani · 2020 · Journal of Cellular Physiology · 643 citations
Abstract One of the most important branches of genetic engineering is the expression of recombinant proteins using biological expression systems. Nowadays, different expression systems are used for...
In vitro plant tissue culture: means for production of biological active compounds
Claudia A. Espinosa-Leal, César A. Puente-Garza, Silverio García‐Lara · 2018 · Planta · 545 citations
A Review of the Microbial Production of Bioactive Natural Products and Biologics
Janette V. Pham, Mariamawit A. Yilma, Adriana Feliz et al. · 2019 · Frontiers in Microbiology · 536 citations
A variety of organisms, such as bacteria, fungi, and plants, produce secondary metabolites, also known as natural products. Natural products have been a prolific source and an inspiration for numer...
Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development
Nagesh K. Tripathi, Ambuj Shrivastava · 2019 · Frontiers in Bioengineering and Biotechnology · 531 citations
Infectious diseases, along with cancers, are among the main causes of death among humans worldwide. The production of therapeutic proteins for treating diseases at large scale for millions of indiv...
Generation of glyco‐engineered <i>Nicotiana benthamiana</i> for the production of monoclonal antibodies with a homogeneous human‐like <i>N</i>‐glycan structure
Richard Strasser, Johannes Stadlmann, Matthias Schähs et al. · 2008 · Plant Biotechnology Journal · 516 citations
Summary A common argument against using plants as a production system for therapeutic proteins is their inability to perform authentic human N ‐glycosylation (i.e. the presence of β1,2‐xylosylation...
Recent advances in (therapeutic protein) drug development
H. A. Daniel Lagassé, Aikaterini Alexaki, Vijaya L. Simhadri et al. · 2017 · F1000Research · 486 citations
<ns4:p>Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to trea...
Reading Guide
Foundational Papers
Start with Varki et al. (1999, 2464 citations) for N-glycan biosynthesis principles; then Strasser et al. (2008, 516 citations) for RNAi engineering in Nicotiana benthamiana; Cox et al. (2006) for Lemna minor glycan optimization.
Recent Advances
Strasser (2016, 435 citations) reviews plant protein glycosylation advances; Shaaltiel et al. (2007, 417 citations) on therapeutic enzyme production with mannose glycans.
Core Methods
RNA interference silences XylT/FucT; overexpression of human GalT, ST3Gal; glycan analysis via MALDI-TOF MS; transient agroinfiltration in Nicotiana benthamiana (Strasser et al., 2008; Cox et al., 2006).
How PapersFlow Helps You Research Glycosylation Engineering in Transgenic Plants
Discover & Search
Research Agent uses searchPapers('glycosylation engineering transgenic plants') to find Strasser et al. (2008), then citationGraph reveals 516 citing papers on N-glycan humanization, while findSimilarPapers identifies glyco-engineered Nicotiana benthamiana works and exaSearch uncovers Lemna minor optimizations like Cox et al. (2006).
Analyze & Verify
Analysis Agent applies readPaperContent on Strasser et al. (2008) to extract RNAi knockdown efficiencies for XylT/FucT, verifies glycan structure claims via verifyResponse (CoVe) against Varki et al. (1999), and runs PythonAnalysis to quantify N-glycan profiles from supplementary data using pandas for immunogenicity risk assessment with GRADE scoring.
Synthesize & Write
Synthesis Agent detects gaps in scaling glyco-engineered plants beyond Nicotiana via contradiction flagging between Strasser (2016) and production papers, while Writing Agent uses latexEditText for glycan pathway diagrams, latexSyncCitations for 20+ references, and latexCompile to generate a review manuscript with exportMermaid for N-glycosylation engineering workflows.
Use Cases
"Analyze N-glycan profiles from Strasser 2008 supplementary data for human compatibility"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib quantifies xylose/fucose peaks) → GRADE-verified glycan homogeneity report with statistical p-values.
"Draft LaTeX figure of glyco-engineered Nicotiana benthamiana pathway"
Synthesis Agent → gap detection → Writing Agent → latexEditText (edits TikZ glycan diagram) → latexSyncCitations (adds Strasser et al. 2008) → latexCompile → PDF with humanized N-glycan workflow diagram.
"Find GitHub code for plant glycosylation simulation models"
Research Agent → paperExtractUrls (Strasser 2016) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs Python kinetic models for glycosyltransferase rates with NumPy simulations.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers on plant glycosylation engineering, chaining searchPapers → citationGraph → DeepScan for 7-step analysis of Strasser et al. (2008) with CoVe checkpoints on glycan claims. Theorizer generates hypotheses for sialylation pathway insertion in Lemna minor by synthesizing Cox et al. (2006) with Varki et al. (1999), producing testable metabolic models via exportMermaid.
Frequently Asked Questions
What defines glycosylation engineering in transgenic plants?
It modifies plant N-glycosylation by silencing XylT/FucT genes and adding human glycosyltransferases to eliminate immunogenic plant glycans and produce GnGn or sialylated structures (Strasser et al., 2008).
What methods humanize plant N-glycans?
RNAi knockdown of β1,2-xylosyltransferase and α1,3-fucosyltransferase in Nicotiana benthamiana yields homogeneous human-like GnGn N-glycans on monoclonal antibodies (Strasser et al., 2008); human GalT and sialyltransferase expression in Lemna minor adds terminal galactosylation (Cox et al., 2006).
What are key papers?
Strasser et al. (2008, 516 citations) on glyco-engineered Nicotiana benthamiana; Cox et al. (2006, 417 citations) on Lemna minor antibody optimization; Strasser (2016, 435 citations) reviews plant glycosylation; Varki et al. (1999, 2464 citations) covers glycobiology fundamentals.
What open problems exist?
Full sialylation pathways compete with plant metabolism; scaling yields for clinical GMP production; ensuring consistent glycan occupancy across glycoproteins (Strasser, 2016; Shaaltiel et al., 2007).
Research Transgenic Plants and Applications with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Glycosylation Engineering in Transgenic Plants with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers